Once For All to Acquire Nalanda Global
4.4.2024 09:00:00 EEST | Business Wire | Press release
Once For All (the “Company”), a European leader in supply chain compliance and sustainable sourcing solutions for the built environment, is excited to announce the acquisition of Nalanda Global (“Nalanda”), a leading supply chain risk and compliance management software platform in Spain.
The transaction extends Once For All’s European footprint into Spain and enhances the differentiated offering of its technology platform, adding scale and the ability to aid in providing a broader product suite to its customer base. Similar to Once For All, Nalanda operates a SaaS-based network that helps enable contractors in multiple industries to manage the compliance of sub-contractors in their supply chain. Nalanda also brings additional worker-level compliance and health & safety solutions to Once For All’s product suite.
Founded in 2000 by a group of preeminent Spanish construction companies, Nalanda is based in Madrid, Spain, and its international presence currently extends across more than ten countries in Europe and Latin America. Its solutions are used by large companies across a variety of engineering-related sectors including construction and facilities management. With a network of over 1,000 contractors and 45,000 sub-contractors as of December 2023, Nalanda has one of the largest digital communities of suppliers globally.
GTCR, a leading private equity firm, acquired Once For All in 2023 in partnership with Chief Executive David Hornsby. PSG Equity, a growth equity firm that partners with software and technology-enabled services companies, acquired a majority stake in Nalanda in 2021. As part of the transaction, which is expected to close in the coming weeks, the PSG funds will retain a minority stake in the combined business.
David Hornsby, Chief Executive of Once For All, said:
“Nalanda is a well-established provider with a product suite that strategically complements our own, and we are enthusiastic about combining our strengths as we continue to grow Once For All across Europe. We are excited to welcome the Nalanda team to Once For All and we look forward to working together.”
Juan Gil Rabadan, Founder and CEO of Nalanda, said:
“Nalanda has gone through a transformative journey over the last three years under PSG’s ownership. Through the investment in people and product, both organically and via M&A, we’ve established Nalanda as an industry leader in supply chain risk and compliance management in Spain, with a growing international presence. We are now thrilled to join Once For All as we share a vision for supporting the built environment globally. We look forward to partnering with the Once For All team and continuing to invest in innovating our technology and capabilities to serve our customers.”
Mark Anderson, Managing Director and Head of Technology, Media & Telecommunications at GTCR, said:
“The combination of Once for All and Nalanda helps position the business for future growth through a pan-European offering. The combined company provides a leading technology platform and differentiated suite of products to help address the critical supply chain and compliance needs of its customers. We are pleased to partner with the PSG team and look forward to the continued success of the business.”
Dany Rammal, Managing Director at PSG Equity, said:
“PSG is proud to have been part of the journey to create a leading Spain-based software champion. Nalanda’s success to date is a testament to Juan Gil Rabadan’s vision and his entire team’s dedication to scaling the Company’s solution into a comprehensive supply chain risk management and compliance offering. We are excited to be continuing the journey alongside GTCR, David Hornsby and the entire Once For All management team in support of the combined company’s growth journey.”
About Once For All
Once For All is a European leader in supply chain risk management and sustainable sourcing solutions for the construction industry. We help our customers source and track sales opportunities, manage risk and compliance, and provide tools to increase efficiency in their supply chains. Once For All has over 150,000 customers that use its single codebase SaaS solution to search, find and assess future business relationships based on skills, trades and ESG credentials. As a result, Once For All manages one of the largest proprietary ESG data sets in the world. Once For All has over 400 employees, is the market leader in UK and France and has operations in Belgium and Germany. For more information, please visit www.onceforall.com.
About Nalanda Global
Nalanda is a Spanish supplier risk and compliance management platform founded in 2000. It leverages intelligent cloud software to help connect companies and suppliers using a digital platform that enables the smooth exchange and verification of health and safety, due diligence, supplier validation, invoices, ESG and other business information, as well as providing solutions designed to ensure compliance with worker access, and working time. Nalanda operates in Spain, as well as in several European and Latin American countries. For more information, please visit www.nalandaglobal.com.
About GTCR
Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $25 billion in over 270 companies, and the firm currently manages $40 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.
About PSG Equity
PSG is a growth equity firm that partners with software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 135 companies and facilitated 479 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City, London, Madrid, Paris and Tel-Aviv. To learn more about PSG, visit www.psgequity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403942729/en/
Contact information
Once For All
Arun Varma
arun.varma@onceforall.com
Nalanda
Goodwill Comunicación
Javier Herreros
jherreros@goodwill.es
GTCR
Andrew Johnson
Andrew.johnson@gtcr.com
PSG Equity
Prosek Partners
Matthieu Roussellier/Kate Pledger
Pro-psg@prosek.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom